The theory around the metabotropic glutamate receptor 5 (mGluR5) proposed that inhibition of the glutamate receptor would rescue downstream ERK1/2 dependent excessive protein synthesis in FXS (Bear et al., 2004); however, treatment resistance likely occurs downstream of targeted factors (Stoppel et al., 2021). Here, MAPK3 is linked to fragile X syndrome.